ERBB2 and breast carcinoma: Notably, Her2 receptor overexpression is known to be associated with more aggressive subtypes of breast cancer, including the luminal Her2+ (ER+/Her2+) and Her2+ “only” (ER−/Her2+) subtypes [39].